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Sequencing of the Reannotated LMNB2 Gene Reveals Novel
Mutations in Patients with Acquired Partial Lipodystrophy
Robert A. Hegele, Henian Cao, Dora M. Liu, Gary A. Costain, Valentine Charlton-Menys,
N. Wilson Rodger, and Paul N. Durrington
The etiology of acquired partial lipodystrophy (APL, also called “Barraquer-Simons syndrome”) is unknown. Genomic
DNA mutations affecting the nuclear lamina protein lamin A cause inherited partial lipodystrophy but are not found in
patients with APL. Because it also encodes a nuclear lamina protein (lamin B2) and its genomic structure was recently
reannotated, we sequenced LMNB2 as a candidate gene in nine white patients with APL. In four patients, we found three
new rare mutations in LMNB2: intron 1 56GrT, exon 5 c.643GrA (p.R215Q; in two patients), and exon 8 c.1218GrA
(p.A407T). The combined frequency of these mutations was 0.222 in the patients with APL, compared with 0.0018 in a
multiethnic control sample of 1,100 subjects ( ) and 0.0045 in a sample of 330 white controls (57Pp 2.1# 10 Pp
). These novel heterozygous mutations are the ﬁrst reported for LMNB2, are the ﬁrst reported among patients551.2# 10
with APL, and indicate how sequencing of a reannotated candidate gene can reveal new disease-associated mutations.
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Mutations in several genes have been found in patients
with inherited lipodystrophies, including mutations in
LMNA (MIM 150330), PPARG, and ZMPSTE24 in partial
lipodystrophy and mutations in BSCL2 and AGPAT2 in
congenital total lipodystrophy.1–4 However, the potential
genetic contribution to acquiredpartial lipodystrophy(APL,
also called “Barraquer-Simons syndrome” [MIM 608709])
and acquired generalized lipodystrophy (AGL) has not
been established.5,6 A family history is usually absent in
APL and AGL, whereas a wide range of secondary factors
and conditions are often associated.5,6 For instance, sys-
temic lupus erythematosis, dermatomyositis, hypocom-
plementemia, and membranoproliferative glomerulone-
phritis are sometimes seen in patients with APL,6 whereas
panniculitis and various autoimmune diseases are some-
times seen in patients with AGL.5 An unresolved issue is
whether acquired lipodystrophy syndromes have an un-
derlying component of genetic susceptibility.6 Because
such patients are sporadically affected and are typically
not members of multigenerational families with multi-
ple affected members, alternative strategies to classic po-
sitional cloning are required to ﬁnd susceptibility genes.
Candidate-gene sequencing is one strategy to implicate
a susceptibility gene through identiﬁcation of rare DNA
sequence mutations that are present in affected individ-
uals and absent in healthy individuals. Putative biologi-
cal function is a common criterion used to select a candi-
date gene for genomic DNA sequence analysis. For in-
stance, because structural abnormalities in a nuclear en-
velope protein gene—namely, LMNA, encoding lamin A/
C—cause familial partial lipodystrophy type2 (FPLD2 [MIM
151660]), it is possible that mutations might be found in
genes that encode related nuclear envelope proteins in
other lipodystrophy syndromes. In 2001, we used the ge-
nomic information available at that time to develop am-
pliﬁcation primers for candidate genes encoding nuclear
envelope proteins, including LBR, LMNB1, and LMNB2
(MIM 150341), which encode lamin B receptor, lamin B1,
and lamin B2, respectively.7 We then sequenced these can-
didate genes in patients with AGL or APL who had no
mutations in LMNA.7 Although we identiﬁed several com-
mon polymorphisms, we found no disease-causing muta-
tions and concluded that sequence variants affecting the
nuclear lamina proteome were not likely to be associated
with APL or AGL.7
Recent observations suggest that early versions of mam-
malian genome maps underestimated the total numbers
of exons. For instance, new computational algorithms
have revealed thousands of previously unrecognized ex-
ons in mammalian genomes.8 This understanding has ne-
cessitated signiﬁcant reannotation of cDNA and genomic
DNA databases by “stitching” newly identiﬁed exons into
previously annotated genes. On the basis of this biological
reality, we revisited the reannotated genomic structures
of nuclear proteome genes7; in doing so, we found that
LMNB2 had 6 exons identiﬁed in 2001 but 12 exons in
2005 (ﬁg. 1A).
Using new primers, we interrogated the coding regions
of the reannotated LMNB2 gene in nine unrelated patients
with APL (table 1) whose conditions were diagnosed ac-
cording to established criteria.6 Speciﬁcally, subjects had
gradual onset of bilateral subcutaneous fat loss from the
head, neck, upper extremities, and thorax but not the
lower extremities.6 In addition, subjects had supportive
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Figure 1. A, Genomic structure of LMNB2 as it was known in 2001 and 2005 (with respective reference sequence numbers indicated).
Boxes indicate exons, with the exon number shown above. B, Electropherogram tracings of genomic DNA sequences of the LMNB2 gene
from healthy control subjects (top row of sequences) and subjects with APL (lower row of sequences). Normal genomic sequence for
each region is shown above the tracings, in addition to 5′ and 3′ orientation. Mutation names are given below the tracings, with arrows
pointing to mutant heterozygous sequences. The sequence designated c.82GrA in exon 1 was later determined to be a polymorphism
that was seen at relatively high frequency in control subjects of several ethnic backgrounds and was not signiﬁcantly associated with
APL in this sample. C, Schematic diagram of head, rod, and tail domains of lamins B2 and A. Subdomains of the rod domain are shown
as numbered coil domains and numbered “linker” domains (L). The numbers of amino acid residues for each region of each lamin type
are shown in parentheses above the domain maps. The positions of the two LMNB2 missense mutations are shown (arrows). For the
p.R215Q mutation within Coil 1B of the highly conserved rod domain, the homologous regions from lamins B2, A, and B1 are shown
below the map, with the respective amino acid numbers on each side of this conserved region. R215 in lamin B2 and the corresponding
residue in the other lamins are boxed.
diagnostic criteria, including absence of a clear family his-
tory of lipodystrophy and onset of lipodystrophy before
adulthood. Other types of lipodystrophies, including in-
herited varieties such as congenital generalized lipodys-
trophy (CGL [MIM 269700]), FPLD2, or familial partial
lipodystrophy type 3 (FPLD3 [MIM 604367]) and acquired
varieties such as AGL and HIV-associated lipodystrophy,
were excluded. Other associated conditions in the patients
with APL are shown in table 1. In addition, one patient
had dermatomyositis and alopecia areata, one patient had
bilateral carpal tunnel syndrome, one patient was hypo-
thyroid, and the single patient with C3 deﬁciency and
biopsy-proven membranoproliferative glomerulonephri-
tis had received three renal transplants, with subsequent
development of secondary and tertiary hyperparathyroid-
ism. All patients were white. All study subjects provided
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Table 1. Demographic Clinical Attributes of Nine Patients
with APL
Characteristic Value
Demographic:
Mean (range) age [years] 55.4 (26–80)
White 9 (100)
Female sex 7 (78)
Family history of lipodystrophy 0 (0)
Mean (range) age at fat-loss onset [years] 15.6 (5–20)
Mean (range) age at diagnosis of APL [years] 26.4 (9–40)
Affected regions with subcutaneous fat loss:
Face 8 (89)
Neck 9 (100)
Arms 9 (100)
Chest 9 (100)
Abdomen 7 (78)
Thighs 2 (22)
Calves 0 (0)
Associated conditions:
Complement C3 deﬁciency 1 (11)
Glomerulonephritis 1 (11)
Dermatomyositis 2 (22)
Treated type 2 diabetes 5 (56)
Treated hypertension 5 (56)
Type IV or V dyslipoproteinemia 8 (89)
Hepatomegaly 5 (56)
Hirsutism, no. (%) of women 3 (43)
Polycystic ovarian disease, no. (%) of women 2 (29)
Early vascular disease (at age !50 years) 2 (22)
NOTE.—Data are no. (%) of patients, unless otherwise indicated.
Table 2. Ampliﬁcation Primers for Reannotated LMNB2
Gene
Exon(s)
Primer
(5′r3′)
Product
Size
(bp)Forward Reverse
1 GGCGCGGATTGAATGAG GAAACCCCGCGGAAACC 413
2 TGCTGTAGTCCAAGGGGAAG GTGCCAGGATCAGGGTGAC 238
3 and 4 CCTGAGGTGCTCCCTGTG ACAGCCATGAGGGTGGACT 500
5 and 6 CTTGGGCCTGGTGCTTG CAGGGCCCAGAAGTTGG 499
7 TCACCTGGGCCTTGTGAC CCTCCTCCTCACTCTGTGCT 324
8 GGGGCTCCCACTACCAGT CCTGGTCACCCCCATCAG 348
9 GTCACAGTCCTGGTGGCTGA CAAGTCCTGTGCCTCCAGTC 235
10 and 11 GAAGGGGGCTTTGTGGTAG TGTGTGCACGAGCTCACTCT 511
12 GTGGGGGCAGCCATCTAC TGGCTCTGGGTAAAGAAAGG 163
informed consent for DNA analysis, and the Institutional
Review Board of the University of Western Ontario ap-
proved the study (protocol 07920E).
No coding sequence or promoter mutation in LMNA,
PPARG, ZMPSTE24, BSCL2, or AGPAT2 had been found in
genomic DNA sequence of any patient with APL by use
of established protocols.9–11 LMNB2 was originally se-
quenced using primer pairs7 to amplify the ﬁve C-terminal
exons of the presumed total of six exons from the 2001
reference sequence (ﬁg. 1A; GenBank accession numbers
M94362 andM94363). However, in 2005, the reannotated
LMNB2 gene in chromosome 19 was shown to have 12
exons (ﬁg. 1A; GenBank accession numbers NT_011255
and NM_032737). We made new primers to amplify all
12 exons plus 150 nt at each intron-exon boundary of
LMNB2 (table 2). Standard ampliﬁcation conditions were
used for all reactions, including annealing at 60C for each
of 30 cycles. Sequences were read on a Model 3730 Au-
tomated DNA Sequencer (Applied Biosystems). Mutations
were conﬁrmed by a second independent sequencing re-
action performed on a different day.
The frequencies of LMNB2 mutations were determined
in a multiethnic control sample of 1,100 healthy individ-
uals comprising 330 individuals of white descent, 35 in-
dividuals of African descent, 375 individuals of East Indian
descent, and 360 individuals of Chinese descent. Geno-
typing methods are shown in table 3. All genotyping was
performed with blinding to affected status, and sequence-
proven positive controls were run with each reaction. A
random 5% of genotypes were repeated, and no disparities
were found for any genotype call. All statistical analyses
were performed using SAS version 8.1 (SAS Institute). Be-
tween-group comparisons of proportion of discrete vari-
ables and calculations of relative risk for carriers of the
variants were made using x2 contingency analysis. The
nominal P value for signiﬁcance was .05.
Among the nine subjects with APL described in table 1,
we found four heterozygous genomic sequence variants
of LMNB2 in ﬁve subjects (ﬁg. 1B). These variants were
exon 1 c.82GrA, intron 1 6GrT, exon 5 c.643GrA
(p.R215Q; in two patients), and exon 8 c.1218GrA
(p.A407T). None of these LMNB2 variants had been pre-
viously reported in any database.
To determine how speciﬁc these variants were to our
sample of patients with APL, we genotyped our nonli-
podystrophic control samples (table 4). Genotyping con-
ditions are described in table 3. The c.82GrA variant had
frequencies of 0.0091, 0.0, 0.008, and 0.067 in the white,
African, East Indian, and Chinese samples, respectively,
and an overall allele frequency of 0.027 in themultiethnic
control sample. The intron 16CrT and p.A407Tvariants
were not seen in the multiethnic control sample. The
p.R215Q variant was seen in 3 of the 330 white controls
(allele frequency 0.0045) and in 1 of the 375 East Indian
controls (allele frequency 0.0013) but was absent from the
other control samples (overall allele frequency 0.0018).
Allele frequencies were then compared between the APL
and control samples. The observation of one LMNB2
c.82GrA heterozygote among nine subjects with APL in-
dicated an allele frequency (0.056) that was not signiﬁ-
cantly different from the allele frequency in the multi-
ethnic control sample and thewhite subsample (0.027 and
0.0091, respectively; both ). This suggested that, al-P 1 .05
though the c.82GrA variant was relatively uncommon in
normal subjects, it was not signiﬁcantly associated with
APL in this sample; the relative risk (RR) of APL in carriers
of the variant was 2.1 (95% CI 0.35–12.9; ).P 1 .05
However, the combined frequency of the LMNB2 mu-
tations intron 1 6CrT, p.R215Q, and p.A407T in the
nine subjects with APL was 0.222 (4 of 18 alleles) com-
pared with 0.0018 (4 of 2,200 alleles) in all controls
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Table 3. LMNB2 Genotyping Procedures
Variant Method Conditions Diagnostic Readout
c.82GrA Restriction isotyping Ampliﬁcation with primers 5′-GGCGCGGATTGAAT-
GAG-3′ and 5′-TCTCTGAGATCTTGAGCAGGAG-3′; di-
gestion with MslI; electrophoresis in 2% aga-
rose gel
6G allele: single 253-bp fragment;
6A allele: 180- and 73-bp
fragments
Intron 1 6CrT Restriction isotyping Ampliﬁcation with exon 2 primers; digestion with
BsaI; electrophoresis in 2% agarose gel
6C allele: 186- and 52-bp fragments;
6T allele: single 238-bp fragment
c.643GrA (p.R215Q) Restriction isotyping Ampliﬁcation with exons 5 and 6 primers; diges-
tion with MspAI; electrophoresis in 2% agarose
gel
R215: 318- and 181-bp fragments;
Q215: 237-, 181-, and 81-bp
fragments
c.1218GrA (p.A407T) Allele-speciﬁc
ampliﬁcation
SNaPShot procedure (Applied Biosystems) with
primers 5′-CCCACTACCAGTCCCACCT-3′ and 5′-CA-
AGGGCTCCTCCACCTC-3′ and allele-speciﬁc primer
5′-AGCAGCGGCAGGTTGTCC-3′
Fluorometric readout on Applied Bio-
systems 3730 Automated DNA
Sequencer
Table 4. Allele Frequencies in Controls of New Mutations and Variants Found in
the Reannotated LMNB2 Gene among Patients with APL
Variant
Allele Frequency
Overall
( )Np 1,100
White
( )np 330
African
( )np 35
East
Indian
( )np 375
Chinese
( )np 360
c.82GrA .027 .0091 .0 .0080 .067
Intron 1 6CrT .0 .0 .0 .0 .0
Exon 5 c.643GrA (p.R215Q) .0018 .0045 .0 .0013 .0
Exon 8 c.1218GrA (p.A407T) .0 .0 .0 .0 .0
( ) and 0.0045 (3 of 660 alleles) in white7Pp 2.1# 10
controls ( ). Thus, the RR of APL for carriers5Pp 1.2# 10
of these variants compared with all control subjects was
110.1 (95% CI 35.9–271.0); compared with white control
subjects, it was 37.9 (95% CI 12.7–83.3). The clinical fea-
tures of the four subjects with APLwith these three LMNB2
mutations are shown in table 5.
When the three mutations were considered individu-
ally, the presence of p.A407T in one of nine subjects with
APL, together with its complete absence from 1,100 mul-
tiethnic and 330 white control subjects, was signiﬁcant;
the RRs of APL for carriers were 138.5 (95% CI 26.4–138.5)
and 42.3 (95% CI 8.1–42.3) compared with all controls
and the white controls, respectively. The intron 16CrT
mutation had the same RRs of APL for carriers com-
pared with multiethnic and white control samples. The
recurrence of p.R215Q in two of nine unrelated patients
with APL compared with 3 of 330 reference white subjects
was highly signiﬁcant; the RR of APL for white carriers
of the variant was 19.1 (95% CI 4.9–47.7). These two
APL-affected patients who were heterozygous for p.R215Q
had some similarities (e.g., both were women with long-
term diabetes and dyslipidemia) but also some phenotypic
differences (e.g., one had retinopathy and xanthomata,
whereas the other had dermatomyositis, hepatospleno-
megaly, osteoporosis, hirsutism, and alopecia). Interest-
ingly, p.R215Q was also present, albeit at a very low fre-
quency, in the control East Indian sample but not in the
other ethnic groups; RR of APL for carriers compared with
the overall multiethnic control group was 52.5 (95% CI
13.2–147.6). However, we recognize the limitations of RR
calculations for rare alleles and a rare disease phenotype,
especially for a small cohort of patients. Control subjects
with these mutations had been randomly ascertained from
healthy populations and did not have diabetes, hyperten-
sion, or dyslipidemia.
The ﬁndings indicate how resequencing of a candi-
date gene that has been reannotated at the genomic level
can reveal new disease-associated mutations. The new
LMNB2 mutations include two coding-sequence vari-
ants—p.R215Q in two patients with APL and p.A407T in
one patient with APL—and one variant near a newly de-
ﬁned intron-exon boundary (intron 1 6CrT). The high
prevalence of the mutations in the nine patients with APL
and the very low frequency of themutations in the control
samples indicates an extremely strong, nonrandom asso-
ciation between the mutations and the APL phenotype.
Although it has been recognized as a clinical entity for
almost a century, the etiology of APL has been unclear.6
APL was ﬁrst described as a form of progressive lipodys-
trophy.6,12–14 Most reported APL cases have been sporadic,
and the female:male affected ratio is ∼4:1.6 This is similar
to the female bias (or at least clinical recognition) of the
expression of FPLD2.1–3 APL does not segregate as a classic
simple Mendelian trait in families with an affected pro-
band, nor does it typically cluster in families.6,15–17 Dis-
cordance for APL in MZ twins has been noted.18,19 In ad-
dition, the presence of dermatomyositis, systemic lupus
erythematosis, C3 hypocomplementemia, andmembrano-
proliferative glomerulonephritis in some patients with
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Table 5. Clinical Features of Subjects with APL and Rare LMNB2 Mutations
Characteristic
Finding in Subject with Diagnosed APL
APL02 APL03 APL07 APL09
LMNB2 mutation p.R215Q p.R215Q Intron 1 6CrT p.A407T
Present age (years) 40 64 46 59
Age when fat loss began (years) ∼5 ∼16 ∼17 ∼17
Age at APL diagnosis (years) 9 30 27 25
Diabetes, age at onset (years) Yes, 19 Yes, 37 Yes, 27 No
Extent of fat loss Symmetrical, upper body,
to knees
Symmetrical, upper body,
to upper thighs
Symmetrical, arms, legs,
and gluteal region
Symmetrical, upper body,
to upper thighs
Dyslipidemia Type V Type IV Type V Type IV
Hypertension No Yes Yes Yes
Polycystic ovarian syndrome No Yes Yes No
C3 deﬁciency No No No No
Membranoproliferative glomerulonephritis No No No No
C3 nephritogenic factor No No No No
Autoimmune disease No Yes No No
Dermatomyositis No Yes No No
Xanthomata Eruptive on elbows and
knees
No No No
Hirsutism No Yes Yes No
Retinal involvement Yes No No No
Other Bilateral carpal tunnel
syndrome
Hepatosplenomegaly, coro-
nary artery disease, os-
teoporosis, alopecia
Peripheral neuropathy, gas-
troparesis, depression
Cerebral infarct at age 30
years
NOTE.—All subjects shown in the table are white women.
APL6 suggests that such factors might trigger expression
of the disease. These associations are consistent with the
idea that APL represents a complex phenotype, possibly
with a component of genetic susceptibility that requires
the presence of environmental factors or acquired disor-
ders to be expressed. The fact that not all subjects with
APL had LMNB2 mutations indicates possible molecular
heterogeneity; if other associated genes are identiﬁed, it
might be appropriate to divide APL into molecular sub-
types, analogous to FPLD2 and FPLD3.2 Furthermore, the
fact that a few carriers of LMNB2 mutations, particularly
p.R215Q, were found among apparently healthy controls
is consistent with a complex etiology for APL, in which a
susceptibility allele may not be sufﬁcient for expression
of the phenotype, instead requiring the presence of ad-
ditional factors.
LMNB2 was selected as a candidate gene for genomic
sequence analysis in patients with APL because, like LMNA,
which is the causative gene for FPLD2, it encodes a nuclear
envelope constituent. The implication of mutant LMNB2
in APL widens the range of disorders associated with mu-
tations in intermediate ﬁlament proteins20 and, in partic-
ular, increases to four the number of nuclear envelope
proteins that are associated with human diseases.21 Other
nuclear envelope constituents in which mutations are as-
sociated with disease include lamin A/C (numerous lam-
inopathies22), emerin (Emery-Dreifussmuscular dystrophy
[MIM 310300]), and the lamin B receptor (Pelger-Huet
anomaly [MIM 169400] and hydrops-ectopic calciﬁcation-
moth-eaten skeletal dysplasia [MIM 215140]).
The p.R215Q mutation occurs within the rod domain
of lamin B2 (ﬁg. 1C) and alters an arginine residue that is
conserved not only in human lamins A/C and B1 but also
in mouse and zebraﬁsh lamin B2 genes. Furthermore, cer-
tain missense mutations affecting this domain in LMNA
result in a dilated cardiomyopathy phenotype—namely,
p.E203K and p.L215Q—and in Emery-Dreifuss muscular
dystrophy—namely, p.H222P.22 In contrast, the p.A407T
mutation occurs within the much less evolutionarily con-
served tail domain of LMNB2 (ﬁg. 1C); the analogous res-
idue to A407 is a threonine in both lamin A/C and lamin
B1. Furthermore, there are no missense mutations affect-
ing this residue in lamin A/C, althoughmutations in prox-
imal residues p.R386K and p.R401C underlie Emery-Drei-
fuss muscular dystrophy.22 The presence of the intron 1
6CrT variant near an intron-exon boundary suggests
that it might affect RNA splicing. However, functional as-
sessment of any of these mutations would be difﬁcult,
given that the function of lamin B2 is not precisely de-
ﬁned,23–26 particularly in comparison with lamin B1.27 The
range of potential roles of lamin B2 includes supporting
the inner side of the nuclear envelope, stabilizing the nu-
cleus and chromatin, and regulating gene expression.28
Lamin B2 replicates in the 1st min of S-phase.28 The LMNB2
origin of replication is very well characterized, accommo-
dates the deﬁned start site of DNA synthesis, binds to
origin-recognition complexes in living cells and in vitro,
and supports the initiation of DNA synthesis at ectopic
chromosomal locations.28 It is thus possible that muta-
tions that alter the function of lamin B2 might have an
effect on the rate of DNA replication.
In summary, we have demonstrated human disease-as-
sociated mutations in newly deﬁned coding sequences of
a recently reannotated candidate gene, and, in doing so,
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we found the ﬁrst human mutations in LMNB2 and the
ﬁrst mutations in APL. From these studies, APL appears to
behave like a complex trait with a component of genetic
susceptibility, which, in some patients, is mediated by
LMNB2, with the further requirement for any one of sev-
eral secondary associated illnesses or conditions. The ﬁnd-
ings are consistent with possible molecular genetic het-
erogeneity for APL, since ﬁve of nine patients did not have
an LMNB2 mutation. The ﬁndings extend the range of
phenotypes associated with mutations in nuclear enve-
lope components and increase the number of nuclear
envelope components that are associated with disease.
The ﬁndings also implicate a second nuclear lamin gene
in a human lipodystrophy syndrome and suggest that
other acquired lipodystrophy phenotypes, such as HIV-re-
lated or drug-induced lipodystrophies, may be associated
with mutations affecting the nuclear lamina or interacting
proteins. Finally, the ﬁndings suggest that reannotation
of known genes will disclose new coding sequences that
should be examined by genomic sequence analysis to
search for new disease-associated mutations.
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2001 reference sequence [accession numbers M94362 and
M94363] and 2005 reference sequence [accession numbers
NT_011255 and NM_032737])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for LMNA, APL, FPLD2, LMNB2, CGL,
FPLD3, Emery-Dreifussmuscular dystrophy, Pelger-Huetanom-
aly, and hydrops-ectopic calciﬁcation-moth-eaten skeletal
dysplasia)
References
1. Garg A (2004) Acquired and inherited lipodystrophies. NEngl
J Med 350:1220–1234
2. Hegele RA (2004) Phenomics, lipodystrophy, and the meta-
bolic syndrome. Trends Cardiovasc Med 14:133–137
3. Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux
C, Bastard JP (2005) Diseases of adipose tissue: genetic and
acquired lipodystrophies. Biochem Soc Trans 33:1073–1077
4. Hegele RA (2005) Lessons from human mutations in PPARg.
Int J Obes (Lond) Suppl 1 29:S31–S35
5. Misra A, Garg A (2003) Clinical features and metabolic de-
rangements in acquired generalized lipodystrophy: case re-
ports and review of the literature. Medicine (Baltimore) 82:
129–146
6. Misra A, Peethambaram A, Garg A (2004) Clinical features
and metabolic and autoimmune derangements in acquired
partial lipodystrophy: report of 35 cases and review of the
literature. Medicine (Baltimore) 83:18–34
7. Hegele RA, Yuen J, Cao H (2001) Single-nucleotide polymor-
phisms of the nuclear lamina proteome. J Hum Genet 46:
351–354
8. Frey BJ, Mohammad N, Morris QD, Zhang W, Robinson MD,
Mnaimneh S, Chang R, Pan Q, Sat E, Rossant J, Bruneau BG,
Aubin JE, Blencowe BJ, Hughes TR (2005) Genome-wide anal-
ysis of mouse transcripts using exon microarrays and factor
graphs. Nat Genet 37:991–996
9. Cao H, Hegele RA (2000) Nuclear lamin A/C R482Qmutation
in Canadian kindreds with Dunnigan-type familial partial
lipodystrophy. Hum Mol Genet 9:109–112
10. Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele
RA (2002) Cardiomyopathy in congenital complete lipodys-
trophy. Clin Genet 61:283–287
11. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T (2002)
PPARG F388L, a transactivation-deﬁcient mutant, in familial
partial lipodystrophy. Diabetes 51:3586–3590
12. Barraquer-Ferre L (1935) Lipodystrophie progressive: syn-
drome de Barraquer-Simons. Presse Med 86:1672–1674
13. Langhof H, Zabel R (1960) On lipodystrophia progressiva (fol-
low-up study of the case published by A. Simons in 1911 for
the ﬁrst time in German literature) [in German]. Arch Klin
Exp Dermatol 210:313–321
14. Jeune M, Freycon MT, Hermier M, Lamit HJ, Abboud N,
Brunat N (1965) Nephropathies in progressive lipodystrophy
or Barraquer-Simons disease [in French]. Ann Pediatr (Paris)
12:749–758
15. Biasi D, Caramaschi P, Carletto A, Bambara LM (1999) A case
of acquired partial lipodystrophy associated with localized
scleroderma and undifferentiated connective tissue disease.
Rheumatol Int 19:75–76
16. Quecedo E, Febrer I, Serrano G, Martinez-Aparicio A, Aliaga
A (1996) Partial lipodystrophy associated with juvenile der-
matomyositis: report of two cases. Pediatr Dermatol 13:477–
482
17. Ferrarini A, Milani D, Bottigelli M, Cagnoli G, Selicorni A
(2004) Two new cases of Barraquer-Simons syndrome. Am J
Med Genet A 126:427–429
18. Reichel W, Kobberling J, Fischbach H, Scheler F (1976) Mem-
branoproliferative glomerulonephritis with partial lipodys-
trophy: discordant occurrence in identical twins. KlinWoch-
enschr 54:75–81
19. Bier DM, O’Donnell JJ, Kaplan SL (1978) Cephalothoracic
lipodystrophy with hypocomplementemic renal disease: dis-
cordance in identical twin sisters. J Clin Endocrinol Metab
46:800–807
20. Omary MB, Coulombe PA, McLean WH (2004) Intermediate
ﬁlament proteins and their associated diseases. N Engl J Med
351:2087–2100
21. Worman HJ (2005) Components of the nuclear envelope and
their role in human disease. Novartis Found Symp 264:35–42
22. Hegele R (2005) LMNA mutation position predicts organ sys-
tem involvement in laminopathies. Clin Genet 68:31–34
23. Tribioli C, Biamonti G, Giacca M, ColonnaM, Riva S, Falaschi
www.ajhg.org The American Journal of Human Genetics Volume 79 August 2006 389
A (1987) Characterization of human DNA sequences synthe-
sized at the onset of S-phase. Nucleic Acids Res 15:10211–
10232
24. Hoger TH, Zatloukal K,Waizenegger I, Krohne G (1990)Char-
acterization of a second highly conserved B-type lamin pre-
sent in cells previously thought to contain only a single B-
type lamin. Chromosoma 99:379–390
25. Biamonti G, GiaccaM, Perini G, Contreas G, Zentilin L,Weig-
hardt F, Guerra M, Della Valle G, Saccone S, Riva S, Falaschi
A (1992) The gene for a novel human lamin maps at a highly
transcribed locus of chromosome 19 which replicates at the
onset of S-phase. Mol Cell Biol 12:3499–3506
26. Giacca M, Zentilin L, Norio P, Diviacco S, Dimitrova D, Con-
treas G, Biamonti G, Perini G, Weighardt F, Riva S, Falaschi
A (1994) Fine mapping of a replication origin of humanDNA.
Proc Natl Acad Sci USA 91:7119–7123
27. Vergnes L, Peterfy M, Bergo MO, Young SG, Reue K (2004)
Lamin B1 is required for mouse development and nuclear
integrity. Proc Natl Acad Sci USA 101:10428–10433
28. Kusic J, Kojic S, Divac A, Stefanovic D (2005) Noncanonical
DNA elements in the lamin B2 origin of DNA replication. J
Biol Chem 280:9848–9854
